SLC5A2 and atrial fibrillation: In an investigation by Lee et al., SGLT2 inhibitors were compared with DPP4 inhibitors in a cohort of over 61,000 diabetic patients, finding a reduction in new-onset AF risk (HR: 0.68; 95% CI: 0.56–0.83) [23].